These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37509231)

  • 41. AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer.
    Liu W; Li G; Huang D; Qin T
    Transl Oncol; 2024 Sep; 47():102027. PubMed ID: 38954974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Small cell lung cancer heterogeneity and molecular subtypes: biological and clinical relevance].
    Berta J; Ferencz B; Horváth L; Fillinger J; Lantos A; Bogos K; Rényi-Vámos F; Megyesfalvi Z; Döme B
    Magy Onkol; 2023 Sep; 67(3):181-192. PubMed ID: 37768117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted Therapies and Biomarkers in Small Cell Lung Cancer.
    Taniguchi H; Sen T; Rudin CM
    Front Oncol; 2020; 10():741. PubMed ID: 32509576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution.
    Dora D; Rivard C; Yu H; Bunn P; Suda K; Ren S; Lueke Pickard S; Laszlo V; Harko T; Megyesfalvi Z; Moldvay J; Hirsch FR; Dome B; Lohinai Z
    Mol Oncol; 2020 Sep; 14(9):1947-1965. PubMed ID: 32506804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
    Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
    PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Yi Y; Qiu Z; Yao Z; Lin A; Qin Y; Sha R; Wei T; Wang Y; Cheng Q; Zhang J; Luo P; Shen W
    Front Cell Dev Biol; 2021; 9():770811. PubMed ID: 35087829
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer.
    Pandey M; Mukhopadhyay A; Sharawat SK; Kumar S
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188552. PubMed ID: 33892053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
    Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
    Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small cell lung cancer - news in the tumour´s biology.
    Pavlíčková K; Matěj R
    Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L; Chen B; Lin J; Peng J
    Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
    Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
    Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities.
    Yang L; Zhang Z; Dong J; Zhang Y; Yang Z; Guo Y; Sun X; Li J; Xing P; Ying J; Zhou M
    Pharmacol Res; 2023 Aug; 194():106844. PubMed ID: 37392900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lurbinectedin for the treatment of small cell lung cancer.
    Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
    Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Ikematsu Y; Tanaka K; Toyokawa G; Ijichi K; Ando N; Yoneshima Y; Iwama E; Inoue H; Tagawa T; Nakanishi Y; Okamoto I
    Lung Cancer; 2020 Aug; 146():97-104. PubMed ID: 32526603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in the DNA polymerase binding pathway affect the immune microenvironment of patients with small-cell lung cancer and enhance the efficacy of platinum-based chemotherapy.
    Lin A; Mou W; Zhu L; Yang T; Zhou C; Zhang J; Luo P
    Cancer Innov; 2023 Dec; 2(6):500-512. PubMed ID: 38125769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of the TGF-
    Lin A; Zhu L; Jiang A; Mou W; Zhang J; Luo P
    Dis Markers; 2022; 2022():8766448. PubMed ID: 36590751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.